Abiraterone
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 October 2025 to Question 83204, what step he is taking to secure a recurrent budget for abiraterone in high risk, non-metastatic prostate cancer, in the context of it being ranked top priority for routine commissioning at the Clinical Priorities Advisory Group Prioritisation Meeting in 2024-25.
Answered by Dr Zubir Ahmed
We are pleased to confirm that NHS England announced on 16 January that patients with non‑metastatic prostate cancer will now have access to abiraterone in combination with prednisolone, where it is deemed to be clinically beneficial. This development has been made possible by the health service buying and delivering treatments at better value.
This decision marks a major step forward in the Government’s ongoing work to improve cancer outcomes, ensure earlier access to effective treatments, and support men and their families across England.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →